Trucking company owner indicted in $2M credit card scam
A San Diego-area owner-operator was arraigned on Tuesday in an 18-count indictment charging him with bank fraud, money laundering and aggravated identity theft.
Hasan Korkmaz, who owns San Diego Logistics Group Inc. based in Santee, California, carried out a credit card 'bust-out' scam in which seemingly legitimate credit card accounts are established and then are 'busted out' by maxing out the credit line with no intention of paying the balance, according to the U.S. attorney's office representing the Southern District of California.
Prosecutors allege that Korkmaz obtained names, dates of birth, Social Security numbers and other personal information linked to real people and used the information to apply for numerous credit card accounts.
After opening the fraudulent accounts, he allegedly used the cards to charge various businesses, including his own trucking company, with some charges as high as $18,500 for a single transaction.'To perpetuate the scheme, Korkmaz also made fraudulent payments, with checks drawn on accounts with insufficient funds or drawn on non-existent accounts, to the credit card accounts, thereby temporarily restoring the available credit limits,' according to the attorney's office.
'Korkmaz would then incur additional charges on the credit card accounts at or near the maximum credit limits for the accounts.'
Korkmaz is also alleged to have laundered the bank fraud proceeds, including by transferring them to a Turkish bank account he controlled, causing two banks to lose $2.1 million.
According to Federal Motor Carrier Safety Administration registration data, San Diego Logistics Group specializes in hauling refrigerated meat and fresh produce with three tractors and five drivers. It is listed as having an 'inactive' USDOT number.If convicted, Korkmaz faces maximum sentences of 30 years in prison and a $1 million fine for bank fraud, 20 years and $500,000 for money laundering, and a mandatory minimum sentence of two years in prison for aggravated identity theft.
South Florida trucking company owner gets long prison term for Ponzi scheme
California freight forwarder charged with smuggling billions in goods
California trucking company owner pleads guilty to PPP fraud
Click for more FreightWaves articles by John Gallagher.
The post Trucking company owner indicted in $2M credit card scam appeared first on FreightWaves.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Skye Bioscience Shares Nimacimab 'Anatomy of Progress' Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions
Skye also participated in Evercore ISI obesity-focused event panel discussing CB1 and other non-incretin pathways SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) ('Skye'), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced the debut of its 'Anatomy of Progress' nimacimab development update video series and availability of presentations related to the development of its anti-obesity drug, nimacimab, presented in multiple forums at the American Diabetes Association's (ADA) 85th Scientific Sessions held June 20-23, 2025, in Chicago, Illinois. The presentations are accessible at the following link. Skye Video Series: 'Anatomy of Progress' In this four-part video series highlighted below, Skye discusses unmet needs in the obesity therapeutic space, advantages and benefits of its peripheral CB1-receptor-targeting antibody, which is designed to support healthy weight loss, and development progress of this novel CB1-inhibiting molecule. Skye's Chief Executive Officer, Punit Dhillon, commented on the important mechanistic advantages of nimacimab versus other CB1 inhibitors highlighted in this video update series: 'Obesity isn't just a public health crisis, it's a biologically defended state, one that resists traditional treatments requiring smarter and safer interventions. 'At Skye, we're developing nimacimab, a CB1 antibody that targets receptors in the periphery, while remaining greater than 99% excluded from the brain. Unlike the small molecule CB1 inhibitors currently in development, nimacimab's differentiating peripheral restriction has the potential to demonstrate the same weight loss and metabolic benefits previously seen in clinical trials by first-generation CB1 inhibitors, without the significant neuropsychiatric liabilities that continue to plague its small molecule counterparts. So nimacimab is not just another anti-obesity drug, it represents a new frontier in how we think about fat metabolism, safety and long-term care.' The Anatomy of Progress video series is comprised of: Overview – Highlights Skye's positioning and progress in the obesity landscape, noting the differentiation of its allosteric modulating antibody. Chapter 1: Nimacimab – A Differentiated CB1 Inhibitor for Obesity – A review of Skye's highly peripherally-restricted CB1 inhibitor and its potential advantages relative to the incretin class of anti-obesity drugs and small-molecule CB1 inhibitors, with recent preclinical data. Chapter 2: Nimacimab in the Clinic – Reviews Skye's current clinical activity and near-term Phase 2a clinical data readouts. Chapter 3: Market Opportunity for Nimacimab – Discusses input from obesity physicians that frames the distinct opportunity for a non-GLP1 obesity therapeutic with nimacimab's target product profile. Evercore ISI Panel Members of Skye's management team; Punit Dhillon, Puneet Arora, MD, FACE, and Chris Twitty, PhD participated in a non-incretin therapeutics panel at Evercore's concurrent investor-focused obesity event. Hosted by Evercore's equity research analysts, Liisa Bayko and Umer Raffat, the panel featured notable obesity physicians Helena Rodbard, MD, FACP, MACE, and Sean Wharton, MD, PharmD. The panel reviewed the clinical and preclinical experience with the CB1 pathway and nimacimab's peripheral CB1 blockade as well as the broader non-incretin toolkit supporting obesity care beyond the limits of the GLP-1 era. ADA Innovation Hub Title: Mechanistic Insights into Weight Loss and Metabolic Regulation of Obese Mice Treated with Nimacimab, a Peripherally-restricted CB1 Inhibitor In this ADA symposium, Chris Twitty, PhD, CSO, reviewed the distinguishing characteristics of nimacimab, reiterated meaningful weight loss data from a pre-clinical diet-induced obesity model that underscores nimacimab's potential as a standalone obesity treatment and as a combination therapy, and introduced new biomarker data showing important reductions in obesity-induced inflammation and liver steatosis. Poster Title: Nimacimab, a Peripherally Restricted CB1 Inhibitor, Promotes Metabolic Homeostasis in a Diet-Induced Obesity (DIO) Mouse Model as Demonstrated by Weight Loss, Restored Hormonal Regulation, and Reduced Inflammatory Biomarkers This poster highlighted nimacimab's ability to achieve weight reduction and deliver comprehensive metabolic improvements including enhanced body composition, restoration of metabolic homeostasis, and improved hormonal profiles. These studies and presentations highlight that peripheral inhibition of CB1 using a monoclonal antibody that does not cross the blood-brain barrier is effective, and has differentiating yet complementary mechanisms that make it an ideal combination with incretin-based drugs. These presentations are accessible at the following link. About Skye Bioscience Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2 clinical trial ( NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy®). For more information, please visit: Connect with us on X and LinkedIn. CONTACTS Investor Relationsir@ 410-0266 LifeSci Advisors, Mike Moyermmoyer@ 308-4306 Media Inquiries LifeSci Communications, Michael Fitzhugh mfitzhugh@ 234-3889 FORWARD LOOKING STATEMENTS This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, forward-looking statements can be identified by terminology including 'anticipated,' 'plans,' 'goal,' 'focus,' 'aims,' 'intends,' 'believes,' 'can,' 'could,' 'challenge,' 'predictable,' 'will,' 'would,' 'may' or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to: statements concerning Skye's future plans and prospects, any expectations regarding the safety, efficacy, tolerability or combinability of nimacimab, including based on preclinical diet induced obesity (DIO) studies and clinical studies, the timing of the receipt of final data from our clinical studies, the potential market opportunities, the timing and clinical strategy for nimacimab, the planned timing of Skye's anticipated milestones for nimacimab and the company's cash runway. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company's periodic filings with the Securities and Exchange Commission, including in the 'Risk Factors' section of Skye's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking in to access your portfolio
Washington Post
2 hours ago
- Washington Post
The Social Security time bomb is near. No, really, this time.
One thing I've learned by getting old is that dates that sound very far-off will eventually arrive, and the bills payable on those dates will come due. The long-foretold tipping point of Social Security and Medicare into insolvency seemed like science fiction when I first tried to imagine the 2030s, but a new examination of the numbers confirms that the time is almost here.
New York Post
2 hours ago
- New York Post
How a street peddler fooled some of Manhattan's biggest art collectors — and killed off the city's oldest art gallery
Nestled within the mood light of the Jean-Georges restaurant at the Mark, or seated straight-back against a Turkish pillow in the Gallery at the Carlyle, the denizens of the Upper East Side float in a fish-bowl world. Scandals, like personalities, are magnified. Collisions are inevitable. Yet even today, more than 15 years after her resignation from Manhattan's eminent Knoedler gallery and the circus trial that followed, society swims away from Ann Freedman. 'She did turn heads when she walked in,' said documentary filmmaker Barry Avrich of his first encounter with Freedman over 'a few bottles of expensive Montrachet Chardonnay' at the Mark, followed by dinner at Sant Ambroeus on Madison Avenue. 'And people would talk. Nobody was rushing like the old days to see her. Obviously, that had to hurt. She was a pariah.' 12 Math teacher turned master forger, Pei Shen Qian has been accused of forging the names of abstract expressionists like Jackson Pollock, Mark Rothko, Robert Motherwell and Willem de Kooning on at least 70 paintings. In 2016, what had been elite gossip exploded into the art fraud trial of the century. Freedman, the former president of Knoedler & Co. — Manhattan's then-oldest art gallery, founded in 1846 — was accused of facilitating the sale of $80 million in fake art. The plot, involving a pair of Long Island-based con artists and a math teacher turned master forger named Pei-Shen Qian, was audacious in ambition: Allegedly forging the names of abstract expressionists like Jackson Pollock, Mark Rothko, Robert Motherwell and Willem de Kooning on at least 70 paintings. Everyone from museum experts and art scholars to the relatives of the artists themselves fell for it. But the case was settled before Freedman took the stand. She walked. Was she an avaricious conspirator — or merely another victim of the con, as she maintains? The mystery of her guilt will now never be settled. 12 A few of Pei Shen Qian's faked Rothkos. 12 And a real work by abstract expressionist Mark Rothko. Alamy Stock Photo But for an insular and supercilious cadre of blue-chip collectors, there is no question that Freedman is to blame for their embarrassment. Perhaps flamboyant financier Pierre Lagrange spoke for the entire neighborhood when, over drinks at the Carlyle, he allegedly screamed at Freedman: 'I will set your hair on fire!' He was displeased at discovering that the paint on the $17 million Pollock he bought from her wasn't invented until 1957 — the year after Pollock died. Avrich has now written the definitive account of Freedman's fall, and her ambiguous role in the high-culture hustle to trump them all, in 'The Devil Wears Rothko,' out Tuesday. The title references what Avrich calls Freedman's 'very steely, Anna Wintour'-like personality — belied by her rimless glasses, curly gray hair and cashmere wardrobe. 12 Ann Freedman was the director of Knoedler when the fakes came through the gallery, but has insisted she, too, was duped. AP The book is a follow-up to the author's juicy 2020 documentary 'Made You Look: A True Story About Fake Art,' streaming on Netflix. ''The Devil Wears Rothko' charts the explosive demise of New York's oldest and most prestigious art gallery with detailed and salacious insight into one of the world's largest art frauds, involving an '$80 million deception that duped high-profile experts, famous collectors and museums,' Avrich writes. As The Post wrote in 2016, the fraud began in the early 1990s, when a former waiter from Spain, Jose Carlos Bergantiños Diaz, came upon a Chinese artist peddling art on a Manhattan sidewalk. Bergantiños offered to pay the man, Pei-Shen Qian, $500 per painting. 'Bergantiños would make the paintings look older with tea and dirt,' lawyer Luke Nikas, who represented Freedman, said at the time. 'Finally, he would give the art to Glafira Rosales' — his wife, who was a small-time art dealer on Long Island. 12 Before it closed in 2011, following the scandal, Knoedler was New York City's longest standing art gallery. Robert Miller But in 2003, a Pollock that originated with Rosales was deemed a fake by the nonprofit International Foundation for Art Research, leading to a $2 million refund from Knoedler to the buyer. Still, Freedman continued doing business with Rosales. In 2011, Pierre Lagrange sued the gallery over the fake Pollock after Christie's and Sotheby's turned it down for auction. A day later, Knoedler closed its doors. Rosales eventually admitted to moving more than 60 'lost' works by Rothko and others — really painted by Qian — to Knoedler and downtown art dealer Julian Weissman. In 2016, Freedman's attorney told The Post that she too was duped. 12 Domenico De Sole, seen here with wife Eleanor, was one of the high-flying Knoedler clients scammed. Getty Images 12 De Sole is the chairman of Tom Ford's brand. Getty Images But Gregory A. Clarick, a lawyer for De Sole, had doubts. 'The biggest [problem] is that . . . Rosales kept walking in [to Knoedler] with unknown works that had no documentation. This should have signaled that the works were fake,' he told The Post at the time. Avrich's book also serves as a behind-the-scenes making of his film about the case, while diving broadly into the opaque milieu of fine art dealing, the history of forgery and the increasingly high-tech fakes flooding the market. If there's a punchline to the whole affair it's that, while the seething ultra-rich collectors — like Tom Ford chairman Domenico De Sole, private-equity powerhouse John Howard, former US ambassador Nicholas Taubman, casino CEO Frank Fertitta and Lagrange — took hits to their wallets and reputations, the criminally culpable con men mostly got away with it. 12 Hedge funder Pierre Lagrange (center left) sued the gallery over a fake Jackson Pollock after Christie's and Sotheby's turned it down for auction. Greg Kahn Rosales, who peddled the fakes to Freedman, only did three months in the slammer. Bergantiños, fled to Spain, where extradition was denied. Qian fled to China. The playboy Michael Hammer — father of actor Armie Hammer — who owned Knoedler and made a fortune from the fraud, died in 2022 . 'I believe that everybody in this story was guilty of something,' Avrich told the Post. 'The art was hot, and everyone was trading on that.' Following Qian to his apartment in Shanghai, Avrich discovered a room filled with 'hundreds of paintings' leaned against the walls. 12 Glafira Rosales, a small-time Long Island dealer, pleaded guilty to selling the forged artwork. Gabriella Bass 'He claims he's only doing them for himself, he isn't selling them, but who knows,' the author said. Several galleries in China have exhibited Qian's works and, in a surprise turn, he has become a sought after artist. 'I've had dozens of people reach out to me to try and find Qian's paintings to broker them,' said Avrich. 'They say, 'I'll pay you hundreds of thousands of dollars.'' But the majority of the fake art is still with the collectors who bought it and are too humiliated to let it see the light of day. 12 'The Devil Wears Rothko' is on sale Tuesday. 'Some were seized by the FBI and marked as fakes, some were destroyed, but the rest, collectors kept,' Avrich said. 'I asked Domenico de Sole where the Rothko was, and he said, 'It's hanging on my daughter's wall.'' Rosales has had less luck trading on her ill-fame. Ordered to pay $81 million to victims of the fraud, she has seen authorities seize multiple properties, $33 million and more than 200 works of art, including authentic paintings by Sean Scully, Jules Olitski, Ellsworth Kelly and Andy Warhol. She served nine months of house arrest and three years' probation. Rosales was last seen 'working as a bus girl in a restaurant, living in a rented room, struggling to live on a minimal salary,' according to her attorney. 12 'I've had dozens of people reach out to me to try and find Qian's paintings to broker them,' said book author Barry Avrich of the alleged faker (picured). Bloomberg via Getty Images Bergantiños — who according to Avrich, got his start dealing fake beluga caviar (even selling it to auction houses like Sotheby's and Christie's) — has fared better. Safe from the FBI's Art Crime Team, he agreed to meet with Avrich in his home town in Lugo, Spain, where he 'showed no remorse and blamed Rosales.' 'Before trying to sell me a harmonica that he claimed was once owned by Bob Dylan, he offered me advice on buying art: 'I would buy two or three upcoming artists and then sit on the paintings and the value will go up,'' Avrich recounted. 'He added: 'I entered the art world where many are called, but few are chosen.'' As for Freedman, she's still dealing art from a space at 25 East 73rd Street, steps from her old throne at Knoedler. 12 Rosales, who peddled the fakes to Freedman, only did three months in the slammer. REUTERS 'She's been selling art with some fervor for the last decade,' said Avrich. 'But the gallery walls are mostly covered with emerging artists and the odd secondary market blue-chip art that she is selling on behalf of someone's estate.' Although she's still a regular sight on Madison Ave., Freedman keeps a low profile. Her website is out of date, her Instagram is dead and her Facebook hasn't been updated since 2023. Still, the cracks keep on coming. 'Wonderful gallery!' begins one sarcastic Google review. 'They are all so nice! On the way out, a thin, curly, gray haired lady whispered that she could get me a Picasso for $500. I talked her down to $325! Paint was barely dry! It looks great, hanging over the cat litter box!' Nevertheless, Avrich says he's taken flak for not going even harder on Freedman. 'I screened the film for Alec Baldwin,' said Avrich of the actor who, in 2010, bought a $190,000 phony painting by Ross Bleckner from a different unscrupulous dealer. 'He yelled at me as only Alec Baldwin does, saying, 'You treat her like a schoolgirl that did something wrong during recess. You have to be tougher on her,'' Avrich recalled. 'But that wasn't my role. I wasn't making a '60 Minutes' episode, or being Michael Moore. I let her tell her story. The world can decide where things shake out. Where she sits in this is a debate that rages on.'
